🇺🇸 FDA
Patent

US 10954268

Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

granted A61KA61K38/08A61P

Quick answer

US patent 10954268 (Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers) held by RHYTHM PHARMACEUTICALS, INC. expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RHYTHM PHARMACEUTICALS, INC.
Grant date
Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/08, A61P, A61P3/00, A61P3/04